Medtronic (NYSE:MDT - Get Free Report) had its target price boosted by research analysts at BTIG Research from $99.00 to $109.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the medical technology company's stock. BTIG Research's price objective points to a potential upside of 8.18% from the company's previous close.
MDT has been the subject of several other reports. Needham & Company LLC restated a "buy" rating on shares of Medtronic in a research report on Thursday, September 17th. Royal Bank Of Canada reiterated an "outperform" rating and set a $118.00 price target on shares of Medtronic in a report on Wednesday, September 2nd. Robert W. Baird boosted their price objective on shares of Medtronic from $91.00 to $100.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 2nd. Bank of America increased their price objective on Medtronic from $95.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings raised Medtronic from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday, October 19th. Eighteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $104.17.
Read Our Latest Stock Report on Medtronic
Medtronic Stock Performance
Shares of MDT stock opened at $100.76 on Thursday. The business's 50-day moving average price is $94.26 and its 200-day moving average price is $88.48. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The firm has a market capitalization of $128.89 billion, a price-to-earnings ratio of 24.82, a PEG ratio of 2.39 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.
Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analysts' expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts forecast that Medtronic will post 5.98 EPS for the current year.
Insider Buying and Selling at Medtronic
In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Marinaro sold 10,420 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Medtronic
A number of hedge funds have recently bought and sold shares of the company. Meramec Financial Planners LLC raised its position in Medtronic by 4.9% in the 3rd quarter. Meramec Financial Planners LLC now owns 2,171 shares of the medical technology company's stock valued at $187,000 after buying an additional 101 shares during the last quarter. Genesis Private Wealth LLC boosted its holdings in Medtronic by 2.0% during the 3rd quarter. Genesis Private Wealth LLC now owns 5,170 shares of the medical technology company's stock worth $446,000 after acquiring an additional 103 shares during the last quarter. LightSquare Wealth Management LLC grew its stake in shares of Medtronic by 3.6% in the 3rd quarter. LightSquare Wealth Management LLC now owns 2,932 shares of the medical technology company's stock worth $253,000 after acquiring an additional 103 shares in the last quarter. Kennebec Savings Bank grew its stake in shares of Medtronic by 1.2% in the 3rd quarter. Kennebec Savings Bank now owns 9,201 shares of the medical technology company's stock worth $794,000 after acquiring an additional 110 shares in the last quarter. Finally, Petredis Investment Advisors LLC grew its stake in shares of Medtronic by 0.4% in the 3rd quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company's stock worth $2,275,000 after acquiring an additional 114 shares in the last quarter. Institutional investors own 82.06% of the company's stock.
Key Stories Impacting Medtronic
These are some of the MDT stories that stood out recently:
About Medtronic
(
Get Free Report)
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.